Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GPX4 | P36969 | 5/20 | 0.43 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 5/20 | 0.39 |
| ▸ | CACNB1 | Q02641 | 5/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.38 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21159094 | 0.84 | POLB (0.57) | ROCK2CYP3A4GPX4PANK3POLB | |
| SCHEMBL20070968 | 0.81 | CHRNA7 (0.56) | ROCK2CYP3A4GPX4PANK3CHRNA7 | |
| SCHEMBL22811884 | 0.80 | ALDH1A1 (0.54) | ROCK2CYP3A4GPX4POLB | |
| SCHEMBL4874249 | 0.74 | ALDH1A1 (0.53) | ROCK2CYP3A4CACNA2D1CACNB1CACNA1B | |
| SCHEMBL366363 | 0.70 | DPP7 (0.48) | ROCK2CYP3A4 | |
| SCHEMBL370424 | 0.70 | DPP7 (0.48) | ROCK2CYP3A4 | |
| SCHEMBL12091644 | 0.70 | DPP7 (0.48) | ROCK2CYP3A4 | |
| SCHEMBL20970814 | 0.70 | CES2 (0.47) | — | |
| SCHEMBL10215536 | 0.69 | HIF1A (0.53) | PANK3POLB | |
| SCHEMBL18390257 | 0.69 | MEN1 (0.50) | PANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | ROCK2 581/4885CYP3A4 3158/4885GPX4 3938/4885 |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | ROCK2 581/4885CYP3A4 3158/4885GPX4 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.